NCT03352531View on ClinicalTrials.gov

Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 2, 2018

Primary Completion Date

November 30, 2020

Study Completion Date

October 28, 2023

Conditions

Advanced Cancer

Interventions

BIOLOGICAL

AK-105

Anti-PD-1 monoclonal antibody; Subjects will receive AK105 by intravenous administration.

Trial Locations (5)

2010

St Vincent's Hospital, Sydney (The Kinghorn Cancer Centre), Darlinghurst

2170

Liverpool Hospital, Liverpool

2640

Border Medical Oncology, East Albury

4101

ICON Cancer Foundation, South Brisbane

5037

Ashford Cancer Centre Research, Adelaide

All Listed Sponsors

lead

Akesobio Australia Pty Ltd

INDUSTRY

NCT03352531 - Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter